Comparative Clinical and Economical Analysis of Drugs for Primary Prevention of Thrombotic Complications after Orthopaedic Operations

Full Text


Cost minimization analysis was performed on the basis of the efficacy and safety evaluation of dabigatran etexilate (DE, Pradaxa®) versus other common anticoagulants (AC). Total costs including laboratory and instrumental examinations, consultations related to venous thromboembolism (VTE) and post-operative anticoagulation therapy were calculated by the data of 828 individual registration cards. All patients were divided into 2 groups: 761 patients (91.9%) after total hip and knee arthroplasty (1 st group) and 67patients (8.1%) after other orthopaedic operations (2 nd group). In 1 st group costs for drug prophylaxis of VTE and total costs per patient were significantly lower (by 1196.66 and 432.41 rbl, respectively) when DE was used as compared to AC application. After other orthopaedic operations reliable differences neither in costs for drug prophylaxis of VTE nor in total costs per patient were detected. However the significance of obtained results was limited by the number as well as the differences in initial condition of patients.

Full Text

Сравнительный клинико-экономический анализ препаратов для первичной профилактики тромботических осложнений после ортопедических операций


  1. Загородний Н.В. Профилактика тромбоэмболических осложнений у ортопедических больных при эндопротезировании крупных суставов. В кн.: Материалы симпозиума «Профилактика тромбоэмболических осложнений в травматологии и ортопедии». М.; 2002: 34-40.
  2. Корнилов Н.В. Состояние эндопотезирования крупных суставов в РФ. В кн.: Материалы симпозиума с международным участием «Эндопротезирование крупных суставов». М.; 2000: 49-52.
  3. Приказ Министерства здравоохранения и социального развития Российской Федерации от 31 декабря 2010 г. N 1248н «О порядке формирования и утверждении государственного задания на оказание в 2011 году высокотехнологичной медицинской помощи гражданам Российской Федерации за счет бюджетных ассигнований федерального бюджета». Приложение 3. URL: 1155
  4. Geerts W.H., Bergqvist D., Pineo G.F. Heit J.A., Samama C.M., Lassen M.R. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133 (suppl): 381S-453S.
  5. Nicolaides A.N., Fareed J., Kakkar A.K., Breddin H.K., Goldhaber S.Z., Hull R. et al. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int. Angiol. 2006; 25: 101-61.
  6. Профилактика венозных тромбоэмболических осложнений в травматологии и ортопедии. Российские клинические рекомендации. Травматология и ортопедия России. 2012; 1 (63, Приложение): 3-24.
  7. Duran A., Sengupta N., Diamantopoulos A. Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer’s perspective. Pharmacoeconomics. 2012; 30 (2): 87-101.
  8. Botteman M.F., Caprini J., Stephens J.M. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin. Ther. 2002; 24 (11): 1960-86.
  9. Avorn J., Winkelmayer W.C. Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation. 2004; 110 (24 Suppl 1): IV25-32.
  10. Eriksson B., Dahl O., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370 (9591): 949-56.
  11. Eriksson B., Dahl O., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the REMODEL randomized trial. J. Thromb. Haemost. 2007; 5 (11): 2178-85.
  12. Eriksson B., Friedman R. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty. Clin. Appl. Thromb. Hemost. 2009; 15 (Suppl 1): 25S-31S.
  13. Wolowacz S.E., Roskell N.S., Maciver F. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery. Clin. Ther. 2009; 31 (1): 194-212.
  14. McCullagh L., Tilson L., Walsh C., Barry M. A costeffectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics. 2009; 27 (10): 829-46.
  15. Омельяновский В.В., Загородний Н.В., Маргиева А.В. Клинико-экономический анализ эффективности и безопасности методов профилактики тромбоэмболических осложнений при ортопедических вмешательствах. Хирургия. 2010; 5: 72-81.
  16. Кулинчик Т.В., Реброва О.Ю., Маргиева А.В., Авксентьева М.В. Клиническая эффективность и безопасность первичной профилактики тромботических осложнений после ортопедических операций в реальной практике. Вестник травматологии и ортопедии им. Приорова. 2012; 3: 39-47.
  17. Постановление Правительства Российской Федерации от 5 декабря 2008 г. № 913 «О Программе государственных гарантий оказания гражданам Российской Федерации бесплатной медицинской помощи на 2009 год».
  18. Воробьев П.А., ред. Клинико-экономический анализ. М.: Ньюдиамед; 2008.



Abstract: 107


CrossRef: 1

  1. Es’Kin NA, Dergach EV, Pyadushkina EA. Clinical Economic Analysis of the Use of Enoxaparin, Rivaroxaban and Dabigatran Etexilate for Venous Thromboembolism Prophylaxis (VTP) in Patients after Vast Orthopaedic Operations. Vestnik travmatologii i ortopedii imeni N.N. Priorova. 2016;(4):28. doi: 10.32414/0869-8678-2016-4-28-33


Article Metrics

Metrics Loading ...



  • There are currently no refbacks.

Copyright (c) 2013 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies